Following Isis Pharmaceuticals' (IONS -0.14%) strong presentation at the JPMorgan Healthcare Conference, the market sent shares up 8%. Although a lot of attention is on HoFH drug Kynamro, Isis doesn't have all its eggs in one basket, as nine pipeline drugs will reach important benchmarks this year. In this video, Motley Fool health care analyst David Williamson tells investors what the company's 2013 prospects look like.